CLINICAL TRIALS OF ACTIVATED HUMAN LEUKOCYTES

活化人类白细胞的临床试验

• 批准号: 3614808
• 负责人: GEOFFREY R WEISS
• 金额: $ 75.24万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-06-30 至 1991-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3614808
• 关键词: combination cancer therapy; drug adverse effect; human subject; human therapy evaluation; leukocyte activation /transformation; neoplasm /cancer

The Contractor shall perform clinical evaluations of treatment regimens utilizing activated leukocytes sponsored by the Division of Cancer Treatment, NCI, under an investigational new drug application (IND). Specifically, the Contractor shall: 1) determine the antitumor activity of activating agents in combination with activated leukocytes in a variety of human cancers in patients with advanced disease and minimal prior therapy; 2) define the toxicities of activating agents administered in combination with activated leukocytes to patients with advanced cancer; 3) evaluate new methods for activation of leukocytes and determine the antitumor activity of activated leukocytes generated using the new methodology.

承包商应对治疗方案进行临床评价 利用由癌症部门赞助的活化白细胞， 治疗，NCI，根据研究性新药申请（IND）。 具体而言，承包商应：1）确定 活化剂与活化的白细胞组合， 患有晚期疾病和既往治疗最少的患者中的人类癌症; 2)定义活化剂联合给药的毒性 与活化白细胞的晚期癌症患者; 3）评估新的 活化白细胞和测定抗肿瘤活性的方法 使用新方法产生的活化白细胞。